Monjuvi (tafasitamab-cxix) is given by a healthcare provider as an intravenous (IV) infusion using a needle inserted into a vein. You will receive it plus any premedications at a clinic or infusion center. Your first IV infusion will take about 1.5 to 2.5 hours; thereafter, your infusions will usually take 1.5 to 2 hours. You may need to be at the clinic for a longer period of time for preparation and observation.

It is given as an intravenous infusion by a healthcare provider, 2 to 5 times during a 28-day cycle, depending upon your medical condition.

In the clinic, you will receive medicines before the infusion to decrease your risk of an infusion reaction. In studies, most infusion reactions with Monjuvi occurred during the first or second cycle (the first or second month). These reactions may include fever, chills, rash, flushing, shortness of breath, and high blood pressure.

If you don’t have an infusion reaction, premedication may be stopped at a later date. Premedications include medicines like acetaminophen (Tylenol), antihistamines or corticosteroids (for example: prednisone or dexamethasone).

When was Monjuvi approved?

In July 2020, Monjuvi was first approved to be used in combination with lenalidomide (Revlimid), for the treatment of diffuse large B-cell lymphoma (DLBCL) in adults. Monjuvi works with your immune system to help fight this type of lymphoma. This treatment is given on a long-term basis to help you maintain control of your disease.

In June 2025, the FDA approved Monjuvi to treat follicular lymphoma (FL) in adults, combined with lenalidomide and rituximab (Rituxan). This regimen is given in up to twelve, 28-day cycles cycles over one year.

There is no generic option on the U.S. market.

What is the dose of Monjuvi?

The recommended dose of Monjuvi is 12 milligrams (mg) per kilogram (kg) of actual body weight given as an intravenous (IV) infusion based on a specific dosing schedule. You will receive treatment in “cycles”. Each treatment cycle lasts for 28 days. Because Monjuvi dosing is based on your weight, your healthcare provider will determine your exact dose.

Monjuvi dosing schedule for diffuse large B-cell lymphoma (DLBCL) in adults:

• Cycle 1: Monjuvi is given on days 1, 4, 8, 15 and 22.
• Cycles 2 and 3: Monjuvi is given on days 1, 8, 15 and 22.
• Cycle 4 and beyond: Monjuvi is given on days 1 and 15.

Your healthcare provider will determine the number of treatments you should receive.

Monjuvi is used in combination with another medicine called lenalidomide (Revlimid) for DLBCL. Lenalidomide 25 mg oral capsule is taken once a day on days 1 to 21 of each treatment cycle for the first 12 cycles (for about one year).

Monjuvi dosing schedule for follicular lymphoma (FL) in adults:

• Cycle 1 to 3: Monjuvi is given on days 1, 8, 15 and 22.
• Cycles 4 to 12: Monjuvi is given on days 1 and 15.

Monjuvi is used in combination with 2 other medicines called lenalidomide (Revlimid) and Rituximab (Rituxan) for treatment of FL. lenalidomide (Cycles 1 to 12) and rituximab (Cycles 1 to 5).

To learn more about Monjuvi dosing, visit: What is the dose of Monjuvi?

Related questions

• How does Monjuvi work?
• What is the success rate of Monjuvi?
• What is the difference between Truxima and Rituxan?

What are the most common or serious side effects with Monjuvi?

Common side effects

The most common side effects that occurred in at least 20% of patients in DLBCL studies when Monjuvi was given with lenalidomide include:

• neutropenia / low white blood cell count (51%)
• feeling tired / weak / fatigue (38%)
• anemia / low red blood cell count (36%)
• diarrhea (36%)
• low blood platelet count / thrombocytopenia (31%)
• cough (26%)
• fever (24%)
• swelling of the lower legs or hands (24%)
• respiratory tract infection (24%)
• decreased appetite (22%)

The most common side effects that occurred in at least 20% of patients in FL studies when Monjuvi was given with lenalidomide and rituximab include:

• respiratory tract infections (56%)
• diarrhea (38%)
• rash (37%)
• feeling tired / weak / fatigue (34%)
• constipation (29%)
• muscle and bone pain (24%)
• cough (21%)

The most common Grade 3 or 4 laboratory abnormalities (≥ 20%) in FL are decreased neutrophils and decreased lymphocytes.

Serious side effects

If you have serious side effects, your healthcare provider may need to delay or stop your Monjuvi treatment.

Diffuse large B-cell lymphoma (DLBCL)

In DLBCL studies, serious adverse reactions occurred in 52% of patients, with 15% of patients having to stop Monjuvi treatment permanently, and 65% of patients needing to delay treatment.

Serious side effects with Monjuvi when used to treat DLBCL and occurring in 6% or more of patients, included: infections (26%), such as pneumonia (7%) and febrile neutropenia (6%). With febrile neutropenia, you have a high fever with a low white blood cell count, and the risk or severity of an infection may be higher than normal. Fatal adverse reactions occurred in 5% of patients.

Follicular lymphoma (FL)

In FL studies, serious adverse reactions occurred in 33% of patients receiving Monjuvi (including serious infections in 24% of patients), with 11% of patients having to stop Monjuvi treatment permanently, and 74% of patients needing to delay treatment.

Serious side effects with Monjuvi when used to treat FL and occurring in 2% or more of patients, included: kidney insufficiency (3.3%), cancers (2.9%), and febrile neutropenia (2.6%). Fatal adverse reactions occurred in 1.5% of patients, including from COVID-19, sepsis, and adenocarcinoma (a type of cancer).

Tell your healthcare provider right away if you:

• get a fever of 100.4°F (38°C) or above
• have any bruising or bleeding
• develop any signs or symptoms of an infection
• get a fever, chills, flushing, headache, or shortness of breath during an infusion of MonjuviI.

View more information about Monjuvi side effects, precautions and warnings.

This is not all the information you need to know about Monjuvi (tafasitamab-cxix) for safe and effective use and does not take the place of your doctor’s directions. Review the full product information and discuss this information and any questions you have with your doctor or other health care provider.

References

• Salles G, Duell J, González Barca E, et al. Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study. Lancet Oncol. 2020 Jul;21(7):978-988. doi: 10.1016/S1470-2045(20)30225-4.
• Monjuvi prescribing information. Revised 6/2025. MorphoSys. Boston, MA. Accessed June 24, 2025 at https://www.monjuvi.com/pi/monjuvi-pi.pdf
• Monjuvi.com. Safety profile. Accessed Nov. 28, 2022 at https://www.monjuvihcp.com/safety

Read next

See also:

Related medical questions

• What are the names of the BTK inhibitors?
• What's the difference between Kymriah and Yescarta?
• What is Zydelig used for and how does it work?
• What is the difference between Rituxan and Rituxan Hycela?
• What is the success rate of Epkinly?
• How is Rituxan Hycela administered?
• What is the survival rate of Kymriah?
• What is the success rate of Breyanzi?
• What type of drug is Copiktra?
• What type of drug is Yescarta (axicabtagene ciloleucel)?
• Prednisone: What are 12 Things You Should Know?
• What are CHOP and R-CHOP chemotherapy regimens?
• What causes infusion reactions to rituximab?
• Is Adcetris a chemotherapy drug?

Drug information

• Monjuvi Information for Consumers
• Monjuvi prescribing info & package insert (for Health Professionals)
• Side Effects of Monjuvi (detailed)
• Monjuvi user reviews (1)

Related support groups

• Monjuvi (3 questions, 3 members)
• Follicular Lymphoma (17 questions, 15 members)
• Diffuse Large B-Cell Lymphoma (16 questions, 3 members)

Medical Disclaimer